NASDAQ$TMCI

Treace Medical Concepts Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Treace Medical Concepts reported financial results for the first quarter ended March 31, 2022.

Treace Medical Concepts reported a strong start to 2022, with revenue increasing by 55% compared to the same period last year. The company is raising its full year 2022 revenue guidance to $128 million to $133 million.

  • Revenue of $29.0 million, a 55% increase over the same period last year.
  • Gross margin of 81.0%.
  • Direct sales channel contributed 63% of sales, up from 44% in the first quarter 2021.
  • New five-year $150 million loan arrangement secured.

Headline financials

Total Revenue

$29M

Previous: $18.7M+55.3%
EPS (adj)

-$0.16

Previous: -$0.07-128.6%
Gross Margin

81.0%

No prior period
Capital Expenditures

-$1.48M

Previous: -$196K-655.6%
Free Cash Flow

-$10.5M

Previous: -$2.63M-300.2%
Net Income

-$9.04M

Previous: -$2.43M-271.5%
Operating Income

-$8.1M

Previous: -$1.4M-477.5%
Gross Profit

$23.5M

Previous: $15.4M+53.1%
Cash & Equivalents

$98.5M

Previous: $16.2M+507.2%
Total Assets

$147M

Previous: $37.4M+291.9%
Stock-Based Comp

$1.41M

No prior period

Revenue & EPS history

Treace · Revenue · Quarterly

$29M

Q1 2022+55.3%vs Q1 2021
Beat estimate in 11 of 12 quarters(92%)
ActualEstimate

Forward guidance

Treace is raising its full year 2022 revenue guidance to $128 million to $133 million, which represents approximately 36% to 41% growth over the Company’s 2021 revenue.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

-5.8%

Avg return

Earnings day

-5.9%

Avg return

5 days after

-3.7%

Avg return

30 days after

33%

7 / 21 earnings

Positive

+43.3%

Q3 2024

Best reaction

-62.8%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.7%+31.8%+82.3%
Q4 2025-11.0%-30.0%-41.9%
Q3 2025-28.6%-46.6%-56.0%
Q1 2025-9.5%-10.9%-22.9%
Q4 2024-2.1%+0.0%-7.4%
Q3 2024+43.3%+48.1%+42.7%
Q2 2024+2.7%-8.5%-13.9%
Q1 2024-62.8%-60.9%-45.5%
Q4 2023-5.7%-6.4%-8.9%
Q3 2023-42.1%-32.0%-11.4%
Q2 2023-16.9%-20.3%-31.3%
Q1 2023-5.5%-4.9%-0.9%
Q4 2022+21.1%+19.0%+37.5%
Q3 2022+1.9%+16.1%+13.7%
Q2 2022-1.3%+1.0%+10.1%
Q1 2022-14.4%-30.2%-9.3%
Q4 2021-1.0%-7.4%-5.7%
Q3 2021-0.8%-6.6%-28.5%
Q2 2021-3.3%-5.9%-3.2%
Q4 2020+4.7%+14.9%+11.5%
Q1 2021+4.7%+14.9%+11.5%
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro